Literature DB >> 21340152

Long-term response to sulfonylurea in a patient with diabetes due to mutation in the KCNJ11 gene.

Marcio F Vendramini1, Lucimary C Gurgel, Regina S Moisés.   

Abstract

OBJECTIVE: To report the long-term (30-month) effect of the switch from insulin to sulfonylurea in a patient carrying the p.G53D (c.158G>A) mutation in KCNJ11 gene. SUBJECT AND
METHOD: A 29-year-old male patient was diagnosed with diabetes in the third month of life and after identification of a heterozygous p.G53D mutation in the KCNJ11 gene, the therapy was switched from insulin to sulfonylurea.
RESULTS: Long-term follow-up (30 months) showed that good metabolic control was maintained (HbA1c: 6.6%) and the glibenclamide dose could be reduced.
CONCLUSION: Long-term therapy with sulfonylureas in patients with neonatal diabetes due to mutation in the KCNJ11 gene is safe and promotes sustained improvement of glycemic control.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 21340152     DOI： 10.1590/s0004-27302010000800003

Source DB:  PubMed          Journal:  Arq Bras Endocrinol Metabol        ISSN： 0004-2730


  4 in total

1.  No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.

Authors:  D Iafusco; C Bizzarri; F Cadario; R Pesavento; G Tonini; S Tumini; V Cauvin; C Colombo; R Bonfanti; F Barbetti
Journal:  Diabetologia       Date:  2011-08-07       Impact factor: 10.122

Review 2.  Precision Medicine: Long-Term Treatment with Sulfonylureas in Patients with Neonatal Diabetes Due to KCNJ11 Mutations.

Authors:  Lisa R Letourneau; Siri Atma W Greeley
Journal:  Curr Diab Rep       Date:  2019-06-27       Impact factor: 4.810

3.  Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study.

Authors:  Pamela Bowman; Åsta Sulen; Fabrizio Barbetti; Jacques Beltrand; Pernille Svalastoga; Ethel Codner; Ellen H Tessmann; Petur B Juliusson; Torild Skrivarhaug; Ewan R Pearson; Sarah E Flanagan; Tarig Babiker; Nicholas J Thomas; Maggie H Shepherd; Sian Ellard; Iwar Klimes; Magdalena Szopa; Michel Polak; Dario Iafusco; Andrew T Hattersley; Pål R Njølstad
Journal:  Lancet Diabetes Endocrinol       Date:  2018-06-04       Impact factor: 32.069

4.  Changing the Treatment of Permanent Neonatal Diabetes Mellitus from Insulin to Glibenclamide in a 4-Month-Old Infant with KCNJ11 Activating Mutation.

Authors:  Homa Ilkhanipoor; Zohreh Karamizadeh
Journal:  Int J Prev Med       Date:  2013-09
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.